What is Chardan Capital’s Estimate for GANX FY2024 Earnings?

Gain Therapeutics, Inc. (NASDAQ:GANX) – Research analysts at Chardan Capital lifted their FY2024 earnings per share estimates for Gain Therapeutics in a report issued on Tuesday, November 19th. Chardan Capital analyst K. Nakae now expects that the company will earn ($0.99) per share for the year, up from their prior forecast of ($1.01). Chardan Capital has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.04) per share. Chardan Capital also issued estimates for Gain Therapeutics’ FY2025 earnings at ($0.74) EPS.

Several other brokerages have also issued reports on GANX. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Wednesday, October 9th. Oppenheimer reiterated an “outperform” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, August 14th.

Gain Therapeutics Trading Up 6.2 %

NASDAQ GANX opened at $1.72 on Friday. The firm’s fifty day moving average price is $2.06 and its 200 day moving average price is $1.73. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $5.33. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. The company has a market capitalization of $45.62 million, a price-to-earnings ratio of -1.56 and a beta of 0.33.

Institutional Trading of Gain Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its holdings in shares of Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after purchasing an additional 88,236 shares during the period. Renaissance Technologies LLC raised its position in Gain Therapeutics by 154.2% during the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after buying an additional 72,000 shares during the last quarter. Warberg Asset Management LLC acquired a new stake in shares of Gain Therapeutics in the 2nd quarter worth $66,000. Finally, Hohimer Wealth Management LLC acquired a new stake in shares of Gain Therapeutics in the 2nd quarter worth $422,000. 11.97% of the stock is owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.